About

Arena Pharmaceuticals is focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Arena’s proprietary pipeline includes multiple potentially first- or best-in-class programs with broad clinical utility. The most advanced investigational clinical programs are ralinepag (APD811) which will be commencing a Phase 3 program for pulmonary arterial hypertension (PAH) and etrasimod (APD334) which will be commencing a Phase 3 program for ulcerative colitis (UC) and a program in Crohn’s Disease (CD), and which has potential utility for a broad range of immune and inflammatory conditions. Arena is also evaluating olorinab APD371 in Phase 2 for the treatment of visceral pain associated with Crohn’s disease, as well as other drug candidates in earlier research and development stages.  In addition, Arena has several collaborations including Everest Medicines Limited (ralinepag and etrasimod in Greater China and select Asian countries), Axovant Sciences GmbH (nelotanserin – Phase 2), Boehringer Ingelheim International GmbH (undisclosed target – preclinical), Outpost Medicine, LLC (undisclosed target – preclinical), and Eisai Co., Ltd. and Eisai Inc. (Belviq® – marketed product).